Zealand Pharma A/S

299 articles about Zealand Pharma A/S

• Zealand Pharma A/S - Share Buy-Back Program Under Safe Harbour to Aquire Danish Common Stock for Employee Incentive Programs

  6/28/2021

  Zealand has entered an arrangement with Danske Bank A/S to act as exclusive manager under the program.

• Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection

  6/24/2021

  Zealand Pharma A/S a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that ZEGALOGUE® injection 0.6mg/0.6mL is now commercially available in the U.S. in both an auto-injector and prefilled syringe.

• Zealand Pharma to Participate in LifeSci Nordic Biotech Summit

  6/22/2021

  Zealand Pharma A/S today announced that members of its senior management team are scheduled to participate virtually in the LifeSci Nordic Biotech Summit.

• Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

  6/16/2021

  Zealand Pharma today announced that it will present five posters, and one oral presentation, at the upcoming 81st Scientific Sessions of the American Diabetes Association (ADA), which is being held virtually June 25-29, 2021.

• Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

  6/2/2021

  Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

• Zealand Pharma to participate in Jefferies Virtual Healthcare Conference - May 26, 2021

  5/26/2021

  Zealand Pharma A/S a biotechnology company aspiring to change lives through the development of innovative peptide-based medicines, announced that members of its senior management team are scheduled to participate virtually in the Jefferies Virtual Healthcare Conference.

• Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

  5/20/2021

  Zealand Pharma A/S, a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 2,000 divided into 2,000 new shares with a nominal value of DKK 1 each.

• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons - May 14, 2021

  5/14/2021

  Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

• Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection

  5/12/2021

  Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection

• Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10 am ET) to Present First Quarter Results for 2021

  5/5/2021

  Zealand Pharma A/S a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on May 12, 2021 at 4 pm CET following the announcement of results for the first quarter of 2021

• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

  5/3/2021

  Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

• Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

  4/13/2021

  New studies mark an important advancement of Boehringer Ingelheim’s cardiometabolic focus areas obesity and NASH. The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvement.

• 

  FDA Action Alert: Pacira, Zealand, bluebird and Bristol Myers Squibb

  3/22/2021

  Although the beginning of March was fairly slow, the end of the month shows a busy schedule for PDUFA dates for the U.S. FDA. Read on to see what’s on the calendar for this week.
• 

  BioSpace Movers & Shakers, Aug. 7

  8/7/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers.
• 

  BioSpace Global Roundup, July 9

  7/9/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
• 

  Denmark's Zealand Pharma Places Stalking Horse Bid on Valeritas

  2/10/2020

  Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.
• 

  Clinical Catch-Up: September 23-27

  9/30/2019

  It was a moderately busy week for clinical trial news. Here’s a look.
• 

  Zealand's Dasiglucagon Hits the Mark in Phase III Pediatric Hypoglycemia Trial

  9/24/2019

  Shares of Zealand Pharma A/S are climbing in premarket trading after the company posted another late-stage success for dasiglucagon in treating severe hypoglycemia.

• Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

  9/3/2019

  Boehringer Ingelheim and Zealand Pharma A/S, have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand.

• 

  Clinical Catch-up from Last Week: May 13-17

  5/20/2019

  Here's a roundup of some of the top clinical trial news from the previous week.